Cargando…

Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)

BACKGROUND: The objective of this study was to identify prognostic factors for survival in patients with primary diffuse large B-cell lymphoma (DLBCL) of the adrenal gland. METHODS: Thirty one patients diagnosed with primary adrenal DLBCL from 14 Korean institutions and treated with R-CHOP (rituxima...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yu Ri, Kim, Jin Seok, Min, Yoo Hong, Yoon, Dok Hyun, Shin, Ho-Jin, Mun, Yeung-Chul, Park, Yong, Do, Young Rok, Jeong, Seong Hyun, Park, Joon Seong, Oh, Sung Yong, Lee, Suee, Park, Eun Kyung, Jang, Joung-Soon, Lee, Won-Sik, Lee, Hwe-Won, Eom, HyeonSeok, Ahn, Jae-sook, Jeong, Jae-Heon, Baek, Sun Kyung, Kim, Seok Jin, Kim, Won Seog, Suh, Cheolwon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3445827/
https://www.ncbi.nlm.nih.gov/pubmed/22889180
http://dx.doi.org/10.1186/1756-8722-5-49
_version_ 1782243867395883008
author Kim, Yu Ri
Kim, Jin Seok
Min, Yoo Hong
Yoon, Dok Hyun
Shin, Ho-Jin
Mun, Yeung-Chul
Park, Yong
Do, Young Rok
Jeong, Seong Hyun
Park, Joon Seong
Oh, Sung Yong
Lee, Suee
Park, Eun Kyung
Jang, Joung-Soon
Lee, Won-Sik
Lee, Hwe-Won
Eom, HyeonSeok
Ahn, Jae-sook
Jeong, Jae-Heon
Baek, Sun Kyung
Kim, Seok Jin
Kim, Won Seog
Suh, Cheolwon
author_facet Kim, Yu Ri
Kim, Jin Seok
Min, Yoo Hong
Yoon, Dok Hyun
Shin, Ho-Jin
Mun, Yeung-Chul
Park, Yong
Do, Young Rok
Jeong, Seong Hyun
Park, Joon Seong
Oh, Sung Yong
Lee, Suee
Park, Eun Kyung
Jang, Joung-Soon
Lee, Won-Sik
Lee, Hwe-Won
Eom, HyeonSeok
Ahn, Jae-sook
Jeong, Jae-Heon
Baek, Sun Kyung
Kim, Seok Jin
Kim, Won Seog
Suh, Cheolwon
author_sort Kim, Yu Ri
collection PubMed
description BACKGROUND: The objective of this study was to identify prognostic factors for survival in patients with primary diffuse large B-cell lymphoma (DLBCL) of the adrenal gland. METHODS: Thirty one patients diagnosed with primary adrenal DLBCL from 14 Korean institutions and treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) were analyzed. RESULTS: Complete remission (CR) and overall response rate after R-CHOP chemotherapy were 54.8% and 87.0%. The 2-year estimates of overall survival (OS) and progression-free survival (PFS) were 68.3% and 51.1%. In patients achieving CR, significant prolongations of OS (P = 0.029) and PFS (P = 0.005) were observed. Ann Arbor stage had no influence on OS. There was no significant difference in OS between patients with unilateral involvement of adrenal gland and those with bilateral involvement. When staging was modified to include bilateral adrenal involvement as one extranodal site, early stage (I or II) significantly correlated with longer OS (P = 0.021) and PFS (P <0.001). CONCLUSIONS: Contrary to prior reports, our data suggests that outcomes of primary adrenal DLBCL are encouraging using a regimen of R-CHOP, and that achieving CR after R-CHOP is predictive of survival. Likewise, our modified staging system may have prognostic value.
format Online
Article
Text
id pubmed-3445827
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34458272012-09-20 Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL) Kim, Yu Ri Kim, Jin Seok Min, Yoo Hong Yoon, Dok Hyun Shin, Ho-Jin Mun, Yeung-Chul Park, Yong Do, Young Rok Jeong, Seong Hyun Park, Joon Seong Oh, Sung Yong Lee, Suee Park, Eun Kyung Jang, Joung-Soon Lee, Won-Sik Lee, Hwe-Won Eom, HyeonSeok Ahn, Jae-sook Jeong, Jae-Heon Baek, Sun Kyung Kim, Seok Jin Kim, Won Seog Suh, Cheolwon J Hematol Oncol Research BACKGROUND: The objective of this study was to identify prognostic factors for survival in patients with primary diffuse large B-cell lymphoma (DLBCL) of the adrenal gland. METHODS: Thirty one patients diagnosed with primary adrenal DLBCL from 14 Korean institutions and treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) were analyzed. RESULTS: Complete remission (CR) and overall response rate after R-CHOP chemotherapy were 54.8% and 87.0%. The 2-year estimates of overall survival (OS) and progression-free survival (PFS) were 68.3% and 51.1%. In patients achieving CR, significant prolongations of OS (P = 0.029) and PFS (P = 0.005) were observed. Ann Arbor stage had no influence on OS. There was no significant difference in OS between patients with unilateral involvement of adrenal gland and those with bilateral involvement. When staging was modified to include bilateral adrenal involvement as one extranodal site, early stage (I or II) significantly correlated with longer OS (P = 0.021) and PFS (P <0.001). CONCLUSIONS: Contrary to prior reports, our data suggests that outcomes of primary adrenal DLBCL are encouraging using a regimen of R-CHOP, and that achieving CR after R-CHOP is predictive of survival. Likewise, our modified staging system may have prognostic value. BioMed Central 2012-08-13 /pmc/articles/PMC3445827/ /pubmed/22889180 http://dx.doi.org/10.1186/1756-8722-5-49 Text en Copyright ©2012 Kim et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Kim, Yu Ri
Kim, Jin Seok
Min, Yoo Hong
Yoon, Dok Hyun
Shin, Ho-Jin
Mun, Yeung-Chul
Park, Yong
Do, Young Rok
Jeong, Seong Hyun
Park, Joon Seong
Oh, Sung Yong
Lee, Suee
Park, Eun Kyung
Jang, Joung-Soon
Lee, Won-Sik
Lee, Hwe-Won
Eom, HyeonSeok
Ahn, Jae-sook
Jeong, Jae-Heon
Baek, Sun Kyung
Kim, Seok Jin
Kim, Won Seog
Suh, Cheolwon
Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)
title Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)
title_full Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)
title_fullStr Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)
title_full_unstemmed Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)
title_short Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)
title_sort prognostic factors in primary diffuse large b-cell lymphoma of adrenal gland treated with rituximab-chop chemotherapy from the consortium for improving survival of lymphoma (cisl)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3445827/
https://www.ncbi.nlm.nih.gov/pubmed/22889180
http://dx.doi.org/10.1186/1756-8722-5-49
work_keys_str_mv AT kimyuri prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl
AT kimjinseok prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl
AT minyoohong prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl
AT yoondokhyun prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl
AT shinhojin prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl
AT munyeungchul prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl
AT parkyong prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl
AT doyoungrok prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl
AT jeongseonghyun prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl
AT parkjoonseong prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl
AT ohsungyong prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl
AT leesuee prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl
AT parkeunkyung prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl
AT jangjoungsoon prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl
AT leewonsik prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl
AT leehwewon prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl
AT eomhyeonseok prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl
AT ahnjaesook prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl
AT jeongjaeheon prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl
AT baeksunkyung prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl
AT kimseokjin prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl
AT kimwonseog prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl
AT suhcheolwon prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl